2003
DOI: 10.1039/b300717k
|View full text |Cite
|
Sign up to set email alerts
|

[2.2]Paracyclophane derivatives in asymmetric catalysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
107
0

Year Published

2006
2006
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 281 publications
(111 citation statements)
references
References 60 publications
1
107
0
Order By: Relevance
“…[2] These structures are usually derived from metallocenes, including ferrocene, [3] or from the [2.2]paracyclophane (Pc) framework. [4] In transition-metal catalysis, [2.2]paracyclophane has been predominantly recognized as a scaffold for phosphane ligands [5] or for N-heterocyclic carbenes.…”
Section: Introductionmentioning
confidence: 99%
“…[2] These structures are usually derived from metallocenes, including ferrocene, [3] or from the [2.2]paracyclophane (Pc) framework. [4] In transition-metal catalysis, [2.2]paracyclophane has been predominantly recognized as a scaffold for phosphane ligands [5] or for N-heterocyclic carbenes.…”
Section: Introductionmentioning
confidence: 99%
“…Here, even the linear hexanal (4c) showed a reasonable enantiomeric excess with 72 % ee. However, it was not possible to determine the selectivity in the case of undecanal (4b), either by GC on chiral stationary phase, or by 13 C NMR spectroscopy of the (S)-(À)-camphanic acid ester for de determination. Overall, we saw a general trend that the AHPC-based ligands 1 gave better results than ligands 2 derived from BHPC, and in the latter case the (S P ,S)-configurated ligand showed better selectivity than the (R P ,S)-diastereomer.…”
mentioning
confidence: 98%
“…1,2 Perhaps the most famous example is PHANEPHOS, a planar chiral equivalent of BINAP, which, amongst other applications, [3][4][5][6][7] exhibited a higher activity and enantioselectivity than BINAP in the Rh-catalyzed hydrogenation of the tetrahydropyrazine precursor to the HIV protease inhibitor…”
Section: Introductionmentioning
confidence: 99%